Effects of tanshinones mediated by forkhead box O3a transcription factor on the proliferation and apoptosis of lung cancer cells

Liu,Dongjie; Yuan,Renbing; Yang,Fang; Zhang,Dehui

doi:10.3892/ol.2018.9530

Effects of tanshinones mediated by forkhead box O3a transcription factor on the proliferation and apoptosis of lung cancer cells

Authors:
- Dongjie Liu
- Renbing Yuan
- Fang Yang
- Dehui Zhang
View Affiliations

Affiliations: Oncology Department, Daqing Oil Field General Hospital, Daqing, Heilongjiang 163000, P.R. China
Published online on: October 1, 2018 https://doi.org/10.3892/ol.2018.9530
Pages: 450-455

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

According to global cancer statistics in 2012, lung cancer (LC) was the most frequently diagnosed cancer and the leading cause of cancer‑associated mortality among males worldwide. Owing to the limited therapeutic approaches available, novel methods for treating LC are required. Tanshinones (Ts) have previously been proved to be effective in treating cardiovascular disease, inflammatory disease and cancer, and have been reported to regulate cell proliferation and apoptosis of LC. The underlying molecular mechanism of action of Ts remains unclear. Furthermore, forkhead box O3a (FoxO3a) has been reported to be a critical gene in cell apoptosis. Therefore, the A549 lung cancer cell line was transfected with FoxO3a small interfering RNA (siRNA) or scrambled siRNA, and the cells which exhibited the most successful transfection efficacy were selected for further investigation into the underlying molecular mechanism of the influence of Ts on FoxO3a in LC cells. Various concentrations of Ts were assigned to experimental groups I‑IV (5, 10, 20 and 30 µmol/l Ts, respectively). An MTT assay revealed that Ts inhibited cell proliferation in a dose‑ and time‑dependent manner compared with the control group (CON; without Ts administration) with a maximal dose of 20 µmol/l at 72 h treatment (P<0.05). Similarly, compared with CON, flow cytometry results revealed that Ts induce LC cell apoptosis in a dose‑dependent manner (P<0.05). Consistently, the expression levels of FoxO3a mRNA and protein were restored following treatment with Ts in a dose‑dependent manner, alongside caspase‑3 activation. On the basis of these results, we hypothesize that Ts regulate LC cell proliferation and apoptosis by triggering an apoptotic cascade through the FoxO3a/caspase‑3 signaling pathway.

View Figures

View References

1	Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
2	Hirsch FR, Franklin WA, Gazdar AF and Bunn PA Jr: Early detection of lung cancer: Clinical perspectives of recent advances in biology and radiology. Clin Cancer Res. 7:5–22. 2001.PubMed/NCBI
3	Spira A and Ettinger DS: Multidisciplinary management of lung cancer. N Engl J Med. 350:379–392. 2004. View Article : Google Scholar : PubMed/NCBI
4	Ho C, Ramsden K, Zhai Y, Murray N, Sun S, Melosky B and Laskin J: Less toxic chemotherapy improves uptake of all lines of chemotherapy in advanced non-small-cell lung cancer: A 10-year retrospective population-based review. J Thorac Oncol. 9:1180–1186. 2014. View Article : Google Scholar : PubMed/NCBI
5	van der Greef J: Perspective: All systems go. Nature. 480:S872011. View Article : Google Scholar : PubMed/NCBI
6	Wu J, Tang Q, Zhao S, Zheng F, Wu Y, Tang G and Hahn SS: Extracellular signal-regulated kinase signaling-mediated induction and interaction of FOXO3a and p53 contribute to the inhibition of nasopharyngeal carcinoma cell growth by curcumin. Int J Oncol. 45:95–103. 2014. View Article : Google Scholar : PubMed/NCBI
7	Jiang WG, Ye L, Ji K, Frewer N, Ji J and Mason MD: Inhibitory effects of Yangzheng Xiaoji on angiogenesis and the role of the focal adhesion kinase pathway. Int J Oncol. 41:1635–1642. 2012. View Article : Google Scholar : PubMed/NCBI
8	Gao L, Li Q, Jiang M, Liu C, Song Z, Bao X, Shen Y, Liu G and Hu K: Combined therapy of percutaneous cryoablation and traditional Chinese medicine can be a promising strategy for elderly or advanced lung cancer patients based on a retrospective clinical study. Cryobiology. 69:174–177. 2014. View Article : Google Scholar : PubMed/NCBI
9	Zhou L, Zuo Z and Chow MS: Danshen: An overview of its chemistry, pharmacology, pharmacokinetics, and clinical use. J Clin Pharmacol. 45:1345–1359. 2005. View Article : Google Scholar : PubMed/NCBI
10	Zheng S, Ren Z, Zhang Y and Qiao Y: Anti-inflammatory mechanism research of tanshinone II A by module-based network analysis. Biomed Mater Eng. 24:3815–3824. 2014.PubMed/NCBI
11	Su CC, Chen GW and Lin JG: Growth inhibition and apoptosis induction by tanshinone I in human colon cancer Colo 205 cells. Int J Mol Med. 22:613–618. 2008.PubMed/NCBI
12	Gong Y, Li Y, Abdolmaleky HM, Li L and Zhou JR: Tanshinones inhibit the growth of breast cancer cells through epigenetic modification of Aurora A expression and function. PLoS One. 7:e336562012. View Article : Google Scholar : PubMed/NCBI
13	Li Y, Gong Y, Li L, Abdolmaleky HM and Zhou JR: Bioactive tanshinone I inhibits the growth of lung cancer in part via downregulation of Aurora A function. Mol Carcinog. 52:535–543. 2013. View Article : Google Scholar : PubMed/NCBI
14	Shang Q, Xu H and Huang L: Tanshinone IIA: A promising natural cardioprotective agent. Evid Based Complement Alternat Med. 2012:7164592012. View Article : Google Scholar : PubMed/NCBI
15	Chiu TL and Su CC: Tanshinone IIA induces apoptosis in human lung cancer A549 cells through the induction of reactive oxygen species and decreasing the mitochondrial membrane potential. Int J Mol Med. 25:231–236. 2010.PubMed/NCBI
16	Lee CY, Sher HF, Chen HW, Liu CC, Chen CH, Lin CS, Yang PC, Tsay HS and Chen JJ: Anticancer effects of tanshinone I in human non-small cell lung cancer. Mol Cancer Ther. 7:3527–3538. 2008. View Article : Google Scholar : PubMed/NCBI
17	Hou J, Chong ZZ, Shang YC and Maiese K: FOXO3a governs early and late apoptotic endothelial programs during elevated glucose through mitochondrial and caspase signaling. Mol Cell Endocrinol. 321:194–206. 2010. View Article : Google Scholar : PubMed/NCBI
18	Zhao GX, Xu LH, Pan H, Lin QR, Huang MY, Cai JY, Ouyang DY and He XH: The BH3-mimetic gossypol and noncytotoxic doses of valproic acid induce apoptosis by suppressing cyclin-A2/Akt/FOXO3a signaling. Oncotarget. 6:38952–38966. 2015. View Article : Google Scholar : PubMed/NCBI
19	Chiacchiera F and Simone C: The AMPK-FoxO3A axis as a target for cancer treatment. Cell Cycle. 9:1091–1096. 2010. View Article : Google Scholar : PubMed/NCBI
20	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
21	Kruger NJ: The bradford method for protein quantitation. Methods Mol Biol. 32:9–15. 1994.PubMed/NCBI
22	Herzog CR, Blake DC Jr, Mikse OR, Grigoryeva LS and Gundermann EL: FoxO3a gene is a target of deletion in mouse lung adenocarcinoma. Oncol Rep. 22:837–843. 2009. View Article : Google Scholar : PubMed/NCBI
23	Blake DC Jr, Mikse OR, Freeman WM and Herzog CR: FOXO3a elicits a pro-apoptotic transcription program and cellular response to human lung carcinogen nicotine-derived nitrosaminoketone (NNK). Lung Cancer. 67:37–47. 2010. View Article : Google Scholar : PubMed/NCBI
24	Liu HB, Gao XX, Zhang Q, Liu J, Cui Y, Zhu Y and Liu YF: Expression and prognostic implications of FOXO3a and Ki67 in lung adenocarcinomas. Asian Pac J Cancer Prev. 16:1443–1448. 2015. View Article : Google Scholar : PubMed/NCBI
25	Zheng F, Tang Q, Wu J, Zhao S, Liang Z, Li L, Wu W and Hann S: p38α MAPK-mediated induction and interaction of FOXO3a and p53 contribute to the inhibited-growth and induced-apoptosis of human lung adenocarcinoma cells by berberine. J Exp Clin Cancer Res. 33:362014. View Article : Google Scholar : PubMed/NCBI
26	Ho TF and Chang CC: A promising ‘TRAIL’ of tanshinones for cancer therapy. Biomedicine (Taipei). 5:232015. View Article : Google Scholar : PubMed/NCBI
27	Ma ZL, Zhang BJ, Wang DT, Li X, Wei JL, Zhao BT, Jin Y, Li YL and Jin YX: Tanshinones suppress AURKA through up-regulation of miR-32 expression in non-small cell lung cancer. Oncotarget. 6:20111–20120. 2015.PubMed/NCBI
28	Gao H, Sun W, Zhao W, Hao W, Leung CH, Lu J and Chen X: Total tanshinones-induced apoptosis and autophagy via reactive oxygen species in lung cancer 95D cells. Am J Chin Med. 43:1265–1279. 2015. View Article : Google Scholar : PubMed/NCBI
29	Alagia A and Eritja R: siRNA and RNAi optimization. Wiley Interdiscip Rev RNA. 7:316–329. 2016. View Article : Google Scholar : PubMed/NCBI
30	Shang YC, Chong ZZ, Hou J and Maiese K: The forkhead transcription factor FOXO3a controls microglial inflammatory activation and eventual apoptotic injury through caspase 3. Curr Neurovasc Res. 6:20–31. 2009. View Article : Google Scholar : PubMed/NCBI